A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
Year: 2014
Type: article
Study design: Clinical Trial
Source: Gynecologic Oncology
Institutions: Washington University in St. Louis, Roswell Park Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, The Ohio State University, University of Oklahoma Health Sciences Center, University of Iowa, University of Iowa Hospitals and Clinics, Queensland University of Technology, University of Colorado Denver, Duke University, Duke Medical Center, The Hospital of Central Connecticut
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Cleveland Clinic, Cleveland Clinic Foundation, University of Oklahoma, Rush University, NRG Oncology, National Institutes of Health, University of North Carolina at Chapel Hill, University of Oklahoma Health Sciences Center, Cancer Center, University of Colorado, National Health and Medical Research Council, National Cancer Institute
Awards: Gynecologic Oncology Group Specimen Banking, G1950154987, G359183106, GYNECOLOGIC ONCOLOGY GROUP STATISTICAL AND DATA CENTER, Targeted Therapy for Endometrial Cancer, G4285681, NRG Oncology Network Group Operations Center, Gynecologic Oncology Group, Lead Academic Participating Site for the Development and Conduct of NCTN Trials, G70736214, SPORE in Endometrial Cancer, G9000111071, NRG Oncology - Statistical and Data Management Center
OpenAlex ID: W1480371337